1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
PAR-25-311: Leveraging Network Infrastructure to Conduct Innovative Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities (UG3/UH3 - Clinical Trial Optional) is sponsored by National Institutes of Health (NIH). This funding opportunity seeks to leverage existing network infrastructure to conduct innovative research for women, children, pregnant and lactating individuals, and persons with disabilities.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NOT-HD-25-002: Notice Announcing Webinar and Frequently Asked Questions (FAQs) for PAR-25-311 Leveraging Network Infrastructure to Conduct Innovative Research for Women, Children, Pregnant and Lactating Women, and Persons with Disabilities Notice Announcing Webinar and Frequently Asked Questions (FAQs) for PAR-25-311 Leveraging Network Infrastructure to Conduct Innovative Research for Women, Children, Pregnant and Lactating Women, and Persons with Disabilities December 16, 2024 - Leveraging Network Infrastructure to Conduct Innovative Research for Women, Children, Pregnant and Lactating Women, and Persons with Disabilities (UG3/UH3 - Clinical Trial Optional).
See NOFO PAR-25-311 .
Eunice Kennedy Shriver National Institute of Child Health and Human Development ( NICHD ) On December 16, 2024, the Eunice Kennedy Shriver National Institute of Child Health and Human Development issued Notice of Funding Opportunity Announcement (NOFO) PAR-25-311 Leveraging Network Infrastructure to Conduct Innovative Research for Women, Children, Pregnant and Lactating Women, and Persons with Disabilities (UG3/UH3 - Clinical Trial Optional).
This Notice provides information regarding an upcoming pre-application webinar for the above-referenced NOFO. The questions from this webinar will inform Frequently Asked Questions (FAQs) for the above-referenced NOFO. These FAQs will be posted on the Pre-Application Process for NICHD Network Multisite Clinical Research website at the following link: https://www.
nichd. nih. gov/health/clinical-research/clinical-trial-preapplication-process shortly after the webinar.
Webinar Information for PAR-25-311 The webinar will be hosted through Zoom. Participants must register in advance for the webinar through the following link: https://events. gcc.
teams. microsoft. com/event/1cfc5b85-b260-41e7-8800-55c4ed509d6b@14b77578-9773-42d5-8507-251ca2dc2b06, after which a link to join the webinar will be e-mailed to the participant.
The webinar on June 3, 2025 will: Provide an overview of the PAR-25-311 Review the requisite pre-application process Address questions from potential applicants. The planned webinar is optional. Attendance is not required to submit an application in response to the NOFO.
A recording of the webinar will be made available shortly after the webinar at: https://videocast. nih. gov/PastEvents .
All prospective applicants are invited to attend the webinar and are strongly encouraged to send relevant questions prior to the webinar to maximize the use of time. Questions should be emailed to [email protected] by February 1, 2025. These questions will be prioritized during the Q&A portion of the webinar.
While an effort will be made to include all questions in the webinar, it is possible that not all questions will be addressed during the event due to time constraints. Submitted questions and responses from the webinar and those received afterward will be posted at: https://www. nichd.
nih. gov/health/clinical-research/clinical-trial-preapplication-process . Applicants are strongly encouraged to review the FAQs, which may be updated at any time without additional notice, prior to submitting their application.
American Sign Language interpreting services are available upon request. Individuals who need interpreting services and/or other reasonable accommodations to participate in this event, should contact Amy Buckley ( [email protected] ). Requests should be made at least five business days in advance in order to ensure interpreter availability.
Please direct all inquiries to: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Weekly TOC for this Announcement NIH... Turning Discovery Into Health ®
According to the current listing, eligibility includes: Universities and other research institutions are typically eligible for NIH funding opportunities. Confirm the full requirements in the official notice before applying.
Applications for PAR-25-311: Leveraging Network Infrastructure to Conduct Innovative Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities (UG3/UH3 - Clinical Trial Optional) are due November 14, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
PAR-25-311: Leveraging Network Infrastructure to Conduct Innovative Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities (UG3/UH3 - Clinical Trial Optional) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article